Clinical trials: Hemostatic Disorders
Multiple Myeloma
Evaluation of the Spectra Optia® Mononuclear Cell Collection Procedure
The purpose of this investigation is to establish that hematopoetic stem cells collected on a new centrifugal blood separator, CaridianBCT's Spectra Optia Apheresis System, are able to reconstitute the hematopoetic systems of…
- Trial name
- NCT01292486
- Testing
- Spectra Optia Apheresis System
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Terumo BCT
Multiple Myeloma
Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma
The aim of this study is to assess safety, efficacy and pharmacokinetic (PK) parameters with alternative dosing schedules of belantamab mafodotin in combination with bortezomib and dexamethasone compared to the approved dosing…
- Trial name
- DREAMM-16 (NCT07614360)
- Testing
- Belantamab mafodotin, Dexamethasone, Bortezomib
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma, Secondary Immunodeficiency
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants…
- Trial name
- NCT06980480
- Testing
- IGI, 10%
- Where
- 65 sites in United States, Australia and 15 more
- Volunteers
- 183 people
- Sponsor
- Takeda
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Hereditary Hemorrhagic Telangiectasia (HHT)
A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia
This is a Phase 1a/1b, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of TER-1754 (a novel AKT1 inhibitor) in patients with HHT.
- Trial name
- NCT07255846
- Testing
- TER-1754
- Where
- United States
- Sponsor
- Terremoto Biosciences Inc.
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
This phase 2 trial studies the immune response to GEO-CM04S1 (previously designated as COH04S1) compared to standard of care (SOC) mRNA SARS-COV-2 vaccine in patients with blood cancer who have received stem cell transplant or…
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma
- Trial name
- NCT04977024
- Testing
- COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
- Where
- 6 sites in United States
- Volunteers
- 63 people
- Sponsor
- GeoVax, Inc.
Coagulation Disorder
Comparison of Two Point-of-care Devices for Viscoelastic Hemostasis Assays
This study will investigate the correlation and agreement of Quantra-derived parameters with parameters reported by the ROTEM delta and standard laboratory tests in cardiac surgery patients.
- Trial name
- NCT03685097
- Testing
- Quantra System with the QPlus Cartridge
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- HemoSonics LLC
Multiple Myeloma
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)
A Phase I Study of CC-5013 in combination with Doxil, Vincristine and Decadron (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT00091624
- Testing
- CC-5013
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Celgene Corporation
Pancreatic Tumor, Benign, Pancreatic Neoplasms
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst
- Trial name
- LTW (NCT03147768)
- Testing
- Distal Pancreatectomy Sealing Using LTW
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Laser Tissue Welding, Inc.
Multiple Myeloma
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple…
- Trial name
- NCT01711671
- Testing
- DKN-01 300 mg, DKN-01 600 mg, Standard of Care
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Leap Therapeutics, Inc.
Multiple Myeloma
Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma
BMS will conduct a regulatory postmarketing surveillance (PMS) to evaluate the safety of elotuzumab in clinical practice in Japan.
- Trial name
- NCT02976493
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 500 people
- Sponsor
- Bristol-Myers Squibb
Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice
The study will provide information on outcomes in people with multiple myeloma, or systemic AL amyloidosis, or both, under standard care. AL is short for amyloid light-chain.
- Trial name
- DOrianT (NCT04659798)
- Where
- 14 sites in Spain
- Volunteers
- 240 people
- Sponsor
- Takeda
Multiple Myeloma
A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma
The aim of this study is to confirm the comparability of the efficacy and safety profiles of BCD-264 and Darzalex as monotherapy for relapsed and refractory multiple myeloma in subjects previously treated with proteasome…
- Trial name
- DARVIVA (NCT06296121)
- Testing
- BCD-264, Darzalex
- Where
- 14 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Biocad
Multiple Myeloma (MM)
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
To characterize the safety profile of acalabrutinib with and without dexamethasone in subjects with relapsed or refractory Multiple Myeloma (MM)
- Trial name
- NCT02211014
- Testing
- acalabrutinib
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Acerta Pharma BV
Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
The primary purpose of this study is to identify the recommended phase 2 dose (RP2D[s]) and schedule(s) to be safe for JNJ-79635322 in Part 1 (dose escalation), and to characterize the safety and tolerability of JNJ-79635322 at…
- Trial name
- NCT05652335
- Testing
- JNJ-79635322
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 180 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
This study is designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone versus daratumumab in combination with bortezomib/dexamethasone in the Chinese participants with…
- Trial name
- DREAMM 7 (NCT06868654)
- Testing
- Belantamab mafodotin, Daratumumab, Bortezomib
- Where
- 11 sites in China
- Volunteers
- 72 people
- Sponsor
- GlaxoSmithKline
Cancer
A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma
This is a single arm, open-label, Phase Ib/II study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of the oral AKT inhibitor, GSK2110183, when administered to subjects with proteasome inhibitor…
- Trial name
- NCT01445587
- Testing
- Part 1; Cohort 1, Part 1; Cohort 2, Part 2; Stage 1
- Where
- Australia
- Sponsor
- GlaxoSmithKline
Liver Surgery, Liver Dysfunction
Octaplas Pediatric Plasma Replacement Trial
The purpose of this study is to investigate the safety, tolerability and efficacy of octaplas in pediatric patients who require replacement of multiple coagulation factors.
- Conditions
- Liver Surgery, Liver Dysfunction, Coagulopathy, Cardiac Surgery
- Trial name
- NCT02050841
- Testing
- octaplas
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Octapharma
Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma
The purpose of this first in human study is to assess safety, tolerability, PK and preliminary clinical activity and to estimate the MTD(s)/RDE(s) of MIK665 (also referred as S64315) as single agent administered intravenously…
- Trial name
- NCT02992483
- Testing
- MIK665
- Where
- 8 sites in United States, Australia and 5 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma
The 3-drug therapy of Bortezomib-Melphalan-Prednisolone (VMP) is a standard therapy that is commonly used currently in South Korea as a first-line treatment for treatment-naïve patients with multiple myeloma who are ineligible…
- Trial name
- VISION (NCT04151615)
- Where
- 24 sites in South Korea
- Volunteers
- 203 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.